-
公开(公告)号：JP2014050391A
公开(公告)日：2014-03-20
申请号：JP2013211558
申请日：2013-10-09
Applicant: Ucb Pharma Sa , ユセベ ファルマ ソシエテ アノニム
Inventor： ADAMS RALPH , ANDREW GEORGE POPPLEWELL , STEPHEN EDWARD RAPECKI
IPC: C12N15/09 , A61K39/395 , A61P1/02 , A61P1/04 , A61P1/14 , A61P1/16 , A61P1/18 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/10 , A61P11/06 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P25/00 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P33/00 , A61P35/00 , A61P35/02 , A61P37/06 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12P21/08
CPC classification number: C07K16/468 , A61K39/3955 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: PROBLEM TO BE SOLVED: To provide antibody molecules having specificity to epitopes of both IL-17A and IL-17F, therapeutic use of the antibody molecules, and a method of producing the antibody molecules.SOLUTION: There are provided anti-IL-17 antibodies which can bind to both IL-17A and IL-17F. The antibodies can specifically bind to both IL-17A and IL-17F, that is, the antibodies do not bind to the other isoforms of IL-17. The antibodies can inhibit biological activity of both IL-17A and IL-17F. There is also provided use of the antibodies in treatment and/or prevention of diseases mediated by either or both of IL-17A or IL-17F, such as autoimmune disease, inflammatory disease or cancer.
Abstract translation: 要解决的问题：提供对IL-17A和IL-17F的表位具有特异性的抗体分子，抗体分子的治疗用途和产生抗体分子的方法。提供抗IL-17抗体 其可以结合IL-17A和IL-17F。 抗体可以特异性结合IL-17A和IL-17F，即抗体不结合IL-17的其他同种型。 抗体可以抑制IL-17A和IL-17F的生物活性。 还提供了在治疗和/或预防由IL-17A或IL-17F中的任一种或两者介导的疾病（例如自身免疫性疾病，炎性疾病或癌症）中使用抗体。
-
公开(公告)号：JP2013252147A
公开(公告)日：2013-12-19
申请号：JP2013185920
申请日：2013-09-09
Applicant: UCB PHARMA SA
Inventor： RAPECKI STEPHEN EDWARD , POPPLEWELL ANDREW GEORGE , ADAMS RALPH
IPC: C12N15/09 , A61K39/395 , A61K45/00 , A61K47/34 , A61K47/48 , A61P11/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/06 , A61P43/00 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08
Abstract: PROBLEM TO BE SOLVED: To provide an antibody molecule having specificity to an antigenic determinant of IL-17, to provide a therapeutic use of the antibody molecule, and to provide a method for forming the antibody molecule.SOLUTION: A neutralizing antibody including a heavy chain and binding to human IL-17 is regulated so that the variable domain of the heavy chain may contain at least one of a CDR having a sequence represented by SEQ ID NO: 1 as the CDR-H1, a CDR having a sequence represented by SEQ ID NO: 2 as the CDR-H2, and a CDR having a sequence represented by SEQ ID NO: 3 as the CDR-H3.
-
公开(公告)号：WO2013068563A9
公开(公告)日：2014-06-19
申请号：PCT/EP2012072325
申请日：2012-11-09
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , BHATTA PALLAVI , HEYWOOD SAM PHILLIP , HUMPHREYS DAVID PAUL
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
公开(公告)号：WO2010035012A9
公开(公告)日：2011-03-17
申请号：PCT/GB2009002310
申请日：2009-09-25
Applicant: UCB PHARMA SA , ADAMS RALPH , HANCOCK LAURA , HEYWOOD SAM PHILIP
Inventor： ADAMS RALPH , HANCOCK LAURA , HEYWOOD SAM PHILIP
CPC classification number: C07K16/468 , C07K16/18 , C07K16/245 , C07K16/28 , C07K16/2878 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/624 , C07K2317/92
Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab' fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab' fragment and one or more single domain antibodies which may be stabilised by a disulfide bond therebetween.
Abstract translation: 一种多价抗体融合蛋白，其包含对目的抗原具有第一特异性的免疫球蛋白部分，例如Fab或Fab'片段，并且还包含对目的第二抗原具有特异性的两个单结构域抗体（dAb），其中 两个单结构域抗体通过二硫键连接。 还提供了特异的双重特异性抗体融合蛋白，其包含Fab或Fab'片段和一个或多个单结构域抗体，其可以通过它们之间的二硫键来稳定。
-
5.发明申请BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 审中-公开结合蛋白质，包括抗体，抗体衍生物和抗体片段，特别是CD154及其用途
公开(公告)号：WO2008118356A3
公开(公告)日：2008-11-20
申请号：PCT/US2008003735
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA , BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不良免疫应答的疾病。
-
Patent Agency Ranking
公开(公告)号：WO2008047134A3
公开(公告)日：2008-06-12
申请号：PCT/GB2007003983
申请日：2007-10-18
Applicant: UCB PHARMA SA , ADAMS RALPH , POPPLEWELL ANDREW GEORGE , RAPECKI STEPHEN EDWARD
Inventor： ADAMS RALPH , POPPLEWELL ANDREW GEORGE , RAPECKI STEPHEN EDWARD
IPC: C07K16/24 , A61K39/395 , A61P35/00 , A61P37/06 , C12N15/13
CPC classification number: C07K16/468 , A61K39/3955 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对IL-17A和IL-17F的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途和产生所述抗体分子的方法。
-
公开(公告)号：WO2013068563A3
公开(公告)日：2013-06-27
申请号：PCT/EP2012072325
申请日：2012-11-09
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , BHATTA PALLAVI , HEYWOOD SAM PHILLIP , HUMPHREYS DAVID PAUL
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及用于产生所述抗体分子的方法。
-
公开(公告)号：WO2012022982A3
公开(公告)日：2012-06-21
申请号：PCT/GB2011051563
申请日：2011-08-19
Applicant: UCB PHARMA SA , HUMPHREYS DAVID PAUL , PETERS SHIRLEY JANE , ADAMS RALPH , HEADS JAMES
Inventor： HUMPHREYS DAVID PAUL , ADAMS RALPH , HEADS JAMES
IPC: C07K16/00 , A61K39/395
CPC classification number: C07K16/24 , A61K39/39591 , C07K16/00 , C07K2317/40 , C07K2317/52 , C07K2317/522 , C07K2317/53 , C07K2317/94
Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
Abstract translation: 本发明提供了包含至少一个包含CH1结构域和铰链区的重链的IgG4类抗体，其中在每条重链中：a。 在CH1结构域中根据Kabat编号系统编号的第127位的链间半胱氨酸被另一个氨基酸取代; 和b。 位于上铰链区的一个或多个氨基酸被半胱氨酸取代。
-
公开(公告)号：CA2773286C
公开(公告)日：2020-10-20
申请号：CA2773286
申请日：2010-09-24
Applicant: UCB PHARMA SA
Inventor： ADAMS RALPH , HANCOCK LAURA , HEYWOOD SAM PHILIP
Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab' fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest which are a VH/VL pair, wherein the two single domain antibodies are linked by a disulfide bond. Also provided are particular dual specificity antibody fusion proteins and other antibody fragments which are stabilised by a disulfide bond.
-
公开(公告)号：NO344847B1
公开(公告)日：2020-05-25
申请号：NO20083066
申请日：2008-07-08
Applicant: UCB PHARMA SA
Inventor： GELINAS RICHARD EVAN , SINGHAL MITRA CHOUDHURY , ZHANG YI , POPPLEWELL ANDREW GEORGE , ADAMS RALPH
IPC: C07K16/24 , A61K39/395 , C12N15/11
-
-
-
-
-
-
-
-
-
Search Results
130
records
(took 0.024 seconds)
